Sondrel’s tech value is doubling after reports that it played a key role in Elon Musk’s Neuralink brain chip
Brain chip: Sondrel shares rise 105.9% after Mail Online reveals it helped develop Neuralink brain chip
The value of Aim-listed Sondrel has doubled following reports that it played a key role in Elon Musk’s Neuralink brain chip.
Shares in Berkshire rose 105.9 per cent, or 6.3p, to 12.25p, adding more than £5m to its £5m market value, after the Mail Online revealed Sondrel had helped with semiconductor technology that allows… Neuralink implants work.
Sondrel is one of the few companies able to supply the chips with the highest specifications required. Others are in Asia and are considered vulnerable to Chinese interference.
Neuralink, founded in 2016, is working on a device that could be integrated into a person’s brain to record and potentially stimulate activity.
Musk said the implants could allow users with disabilities, such as the late Stephen Hawking, to move their bodies using their thoughts.
But safety concerns mean Neuralink is struggling to gain approval for human trials, while some experts have said the technology could be misused in “neuromonitoring”.
It was able to begin testing the chip on humans after getting the green light from the US Food and Drug Administration in September.
According to Mail Online, Neuralink has hired Sondrel for its expertise in designing more complex chips.
Yesterday, Sondrel acknowledged the report and the stock price movement but said it did not comment on the identity of its clients.
“The group’s client base continues to include leading global technology brands,” she added.
The company is led by CEO Graham Coren, who graduated in electronic engineering from the University of Leeds.
He founded Sondrel in 2002 after identifying a gap in the market for a company that specialized in designing complex chips.
(tags for translation) Daily Mail